These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 15639548

  • 1. Indicators of neuroprotection with galantamine.
    Geerts H.
    Brain Res Bull; 2005 Jan 30; 64(6):519-24. PubMed ID: 15639548
    [Abstract] [Full Text] [Related]

  • 2. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity.
    Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, Shimohama S.
    Biochem Biophys Res Commun; 2004 Dec 17; 325(3):976-82. PubMed ID: 15541385
    [Abstract] [Full Text] [Related]

  • 3. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.
    Yanagida T, Takeuchi H, Kitamura Y, Takata K, Minamino H, Shibaike T, Tsushima J, Kishimoto K, Yasui H, Taniguchi T, Shimohama S.
    Neurosci Res; 2008 Dec 17; 62(4):254-61. PubMed ID: 18845194
    [Abstract] [Full Text] [Related]

  • 4. Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases.
    Kawamata J, Shimohama S.
    J Alzheimers Dis; 2011 Dec 17; 24 Suppl 2():95-109. PubMed ID: 21403387
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease.
    Nordberg A.
    Alzheimer Dis Assoc Disord; 2006 Dec 17; 20(2 Suppl 1):S12-8. PubMed ID: 16772751
    [Abstract] [Full Text] [Related]

  • 6. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade.
    Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A.
    Neuropharmacology; 2006 Sep 17; 51(3):474-86. PubMed ID: 16762377
    [Abstract] [Full Text] [Related]

  • 7. [Therapy of Alzheimer disease].
    Kovács T.
    Neuropsychopharmacol Hung; 2009 Mar 17; 11(1):27-33. PubMed ID: 19731816
    [Abstract] [Full Text] [Related]

  • 8. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons.
    Melo JB, Sousa C, Garção P, Oliveira CR, Agostinho P.
    Eur J Neurosci; 2009 Feb 17; 29(3):455-64. PubMed ID: 19222556
    [Abstract] [Full Text] [Related]

  • 9. Preclinical evidence of neuroprotection by cholinesterase inhibitors.
    Akaike A.
    Alzheimer Dis Assoc Disord; 2006 Feb 17; 20(2 Suppl 1):S8-11. PubMed ID: 16772755
    [Abstract] [Full Text] [Related]

  • 10. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
    Pákáski M, Kálmán J.
    Neurochem Int; 2008 Nov 17; 53(5):103-11. PubMed ID: 18602955
    [Abstract] [Full Text] [Related]

  • 11. Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice.
    Unger C, Svedberg MM, Yu WF, Hedberg MM, Nordberg A.
    J Pharmacol Exp Ther; 2006 Apr 17; 317(1):30-6. PubMed ID: 16354790
    [Abstract] [Full Text] [Related]

  • 12. The role of nicotinic acetylcholine receptors in Alzheimer's disease.
    Oddo S, LaFerla FM.
    J Physiol Paris; 2006 Apr 17; 99(2-3):172-9. PubMed ID: 16448808
    [Abstract] [Full Text] [Related]

  • 13. [Nicotinic Receptor, galantamine and Alzheimer disease].
    Arroyo G, Aldea M, Fuentealba J, García AG.
    Rev Neurol; 2006 Apr 17; 34(11):1057-65. PubMed ID: 12134305
    [Abstract] [Full Text] [Related]

  • 14. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT, Edwards KR, Zhao Q.
    J Clin Pharmacol; 2006 Jul 17; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [Abstract] [Full Text] [Related]

  • 15. Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease.
    Abdul HM, Calabrese V, Calvani M, Butterfield DA.
    J Neurosci Res; 2006 Aug 01; 84(2):398-408. PubMed ID: 16634066
    [Abstract] [Full Text] [Related]

  • 16. Galantamine: use in Alzheimer's disease and related disorders.
    Bullock R.
    Expert Rev Neurother; 2004 Mar 01; 4(2):153-63. PubMed ID: 15853556
    [Abstract] [Full Text] [Related]

  • 17. In vitro galantamine-memantine co-application: mechanism of beneficial action.
    Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T.
    Neuropharmacology; 2006 Dec 01; 51(7-8):1181-91. PubMed ID: 17011596
    [Abstract] [Full Text] [Related]

  • 18. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H, Grossberg GT.
    J Clin Pharmacol; 2006 Jul 01; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [Abstract] [Full Text] [Related]

  • 19. Galantamine in Alzheimer's disease.
    Razay G, Wilcock GK.
    Expert Rev Neurother; 2008 Jan 01; 8(1):9-17. PubMed ID: 18088197
    [Abstract] [Full Text] [Related]

  • 20. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
    Deutsch SI, Rosse RB, Schwartz BL, Schooler NR, Gaskins BL, Long KD, Mastropaolo J.
    Eur Neuropsychopharmacol; 2008 Feb 01; 18(2):147-51. PubMed ID: 17656074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.